Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies

Table 1

Randomized trials examining the addition of radiation to ADT for high-risk patients.

Trial	Study cohort	Median; follow-up	Trial arms	Outcomes	Toxicity
Intergroup T94-0110; Warde et al. [6, 7, 10]	1205 patients; (1057 with T3-T4 disease)	8 years	ADT versus ADT + RT (65–69 Gy); ADT: lifelong LHRH agonist or bilateral orchiectomy	10-year OS (45% versus 55%, )	EBRT increased bowel, urinary, and sexual dysfunction at six months, but no difference at 3 years
SPCG-7 Widmark et al. [5]	875 patients T1b-T2 G2-G3 or T3 (78%) and; PSA < 70, N0	7.6 years	ADT versus ADT + RT (median 70 Gy); ADT: 3 months’ GnRH agonist followed by continuous antiandrogen	10-year OS (61% versus 70%, ); 10-year DSS (76% versus 88%, )	RT arm with slightly increased rates of late urinary, GI, and sexual dysfunction at 4 years. Quality of life scores equal at 4 years